Advanced search
1 file | 580.13 KB

Factors associated with 1,25 dihydroxyvitamin D3 concentrations in liver transplant recipients : a prospective observational longitudinal study

Agnieszka Prytula-Ebels (UGent) , Johan Vande Walle (UGent) , Hans Van Vlierberghe (UGent) , Jean Kaufman (UGent) , Tom Fiers (UGent) , Jo Dehoorne (UGent) and Ann Raes (UGent)
(2016) ENDOCRINE. 52(1). p.93-102
Author
Organization
Abstract
The aim of the study was to identify factors associated with 1,25(OH)(2)D-3 concentrations in liver transplant recipients with emphasis on the renal function and catabolism. We also tested the hypothesis that tacrolimus increases 1,25(OH)(2)D-3 concentrations. Serum 25(OH)D-3, 1,25(OH)(2)D-3, and 24,25(OH)(2)D-3 were measured in 41 patients before, at 2 weeks and 3 months after transplantation. Dose-adjusted tacrolimus concentration was used as a surrogate marker of CYP3A4 activity. Factors associated with 1,25(OH)(2)D-3 were identified using multivariate linear regression analysis. The median 1,25(OH)(2)D-3 levels remained stable: 55 versus 46 pg/ml (P = 0.36) despite an increase in 25(OH)D-3 from 18 ng/ml at baseline to 26 ng/ml (P = 0.03), serum albumin (34 to 41 g/l, P = 0.02), and comparable eGFR at baseline and month 3 (94 and 92 ml/min, respectively, P = 0.15). At 3 months 19 % of patients had 1,25(OH)(2)D-3 < 25 pg/ml. Low eGFR and a low dose-adjusted tacrolimus concentration were both independently associated with 1,25(OH)(2)D-3 at 3 months. Liver transplant recipients with impaired renal function or a low dose-adjusted tacrolimus concentration suggesting a high CYP3A4 are at risk of low 1,25(OH)(2)D-3 concentrations. The use of tacrolimus does not lead to an increase in 1,25(OH)(2)D-3 concentrations in a clinical setting.
Keywords
25-Hydroxyvitamin D-3, 1, 25-Dihydroxyvitamin D-3, Tacrolimus, Liver transplantation, D-BINDING-PROTEIN, VITAMIN-D METABOLITES, 25-HYDROXYVITAMIN D, KIDNEY-DISEASE, CYCLOSPORINE-A, BONE-DISEASE, D DEFICIENCY, GC-GLOBULIN, TACROLIMUS, SERUM

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 580.13 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Prytula-Ebels, Agnieszka, Johan Vande Walle, Hans Van Vlierberghe, Jean Kaufman, Tom Fiers, Jo Dehoorne, and Ann Raes. 2016. “Factors Associated with 1,25 Dihydroxyvitamin D3 Concentrations in Liver Transplant Recipients : a Prospective Observational Longitudinal Study.” Endocrine 52 (1): 93–102.
APA
Prytula-Ebels, A., Vande Walle, J., Van Vlierberghe, H., Kaufman, J., Fiers, T., Dehoorne, J., & Raes, A. (2016). Factors associated with 1,25 dihydroxyvitamin D3 concentrations in liver transplant recipients : a prospective observational longitudinal study. ENDOCRINE, 52(1), 93–102.
Vancouver
1.
Prytula-Ebels A, Vande Walle J, Van Vlierberghe H, Kaufman J, Fiers T, Dehoorne J, et al. Factors associated with 1,25 dihydroxyvitamin D3 concentrations in liver transplant recipients : a prospective observational longitudinal study. ENDOCRINE. 2016;52(1):93–102.
MLA
Prytula-Ebels, Agnieszka, Johan Vande Walle, Hans Van Vlierberghe, et al. “Factors Associated with 1,25 Dihydroxyvitamin D3 Concentrations in Liver Transplant Recipients : a Prospective Observational Longitudinal Study.” ENDOCRINE 52.1 (2016): 93–102. Print.
@article{7022389,
  abstract     = {The aim of the study was to identify factors associated with 1,25(OH)(2)D-3 concentrations in liver transplant recipients with emphasis on the renal function and catabolism. We also tested the hypothesis that tacrolimus increases 1,25(OH)(2)D-3 concentrations. Serum 25(OH)D-3, 1,25(OH)(2)D-3, and 24,25(OH)(2)D-3 were measured in 41 patients before, at 2 weeks and 3 months after transplantation. Dose-adjusted tacrolimus concentration was used as a surrogate marker of CYP3A4 activity. Factors associated with 1,25(OH)(2)D-3 were identified using multivariate linear regression analysis. The median 1,25(OH)(2)D-3 levels remained stable: 55 versus 46 pg/ml (P = 0.36) despite an increase in 25(OH)D-3 from 18 ng/ml at baseline to 26 ng/ml (P = 0.03), serum albumin (34 to 41 g/l, P = 0.02), and comparable eGFR at baseline and month 3 (94 and 92 ml/min, respectively, P = 0.15). At 3 months 19 % of patients had 1,25(OH)(2)D-3 < 25 pg/ml. Low eGFR and a low dose-adjusted tacrolimus concentration were both independently associated with 1,25(OH)(2)D-3 at 3 months. Liver transplant recipients with impaired renal function or a low dose-adjusted tacrolimus concentration suggesting a high CYP3A4 are at risk of low 1,25(OH)(2)D-3 concentrations. The use of tacrolimus does not lead to an increase in 1,25(OH)(2)D-3 concentrations in a clinical setting.},
  author       = {Prytula-Ebels, Agnieszka and Vande Walle, Johan and Van Vlierberghe, Hans and Kaufman, Jean and Fiers, Tom and Dehoorne, Jo and Raes, Ann},
  issn         = {1355-008X},
  journal      = {ENDOCRINE},
  keywords     = {25-Hydroxyvitamin D-3,1,25-Dihydroxyvitamin D-3,Tacrolimus,Liver transplantation,D-BINDING-PROTEIN,VITAMIN-D METABOLITES,25-HYDROXYVITAMIN D,KIDNEY-DISEASE,CYCLOSPORINE-A,BONE-DISEASE,D DEFICIENCY,GC-GLOBULIN,TACROLIMUS,SERUM},
  language     = {eng},
  number       = {1},
  pages        = {93--102},
  title        = {Factors associated with 1,25 dihydroxyvitamin D3 concentrations in liver transplant recipients : a prospective observational longitudinal study},
  url          = {http://dx.doi.org/10.1007/s12020-015-0757-9},
  volume       = {52},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: